Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hextar Healthcare Berhad (7803.KL)
Ipoh, MY
Hextar Healthcare Berhad, an investment holding company, produces, sells, and exports household gloves, industrial gloves, and nitrile disposable gloves in Europe, Asia, North and South America, and internationally. The company operates through Gloves Operation, Medical Devices Operation, and Investment Holding segments. It offers latex, neoprene, and two tone gloves. The company also manufactures and trades in in-vitro diagnostics rapid test kits and enzyme-linked immunosorbent assay test kits for detection and diagnoses of infectious diseases and drug-of-abuse screening for medical professionals and the clinical diagnostic markets. In addition, it is involved in the trading of gloves, household and kitchen items, and personal protective products. Hextar Healthcare Berhad was founded in 1987 and is headquartered in Ipoh, Malaysia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +7.14% | +0.00% | -11.76% | -16.67% | -21.05% | -37.50% | -72.22% | -93.53% | -70.59% | -88.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+0.8% Q4'25: -14.7% (vs Q4'24)
-
EPS growth Chemicals - Specialty: +13.2%-206.8% Q4'25: -275.0% (vs Q4'24)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-21.8% Q4'25: +47.7% (vs Q4'24)
-
EBIT margin Chemicals - Specialty: +8.8%-25.1% Q4'25: -59.5% (vs Q4'24)
-
ROIC Chemicals - Specialty: +5.6%-8.6% Q4'25: -19.6% (vs Q4'24)
-
Share dilution Chemicals - Specialty: +0.1%+5.5% Q4'25: +5.5% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×-0.11× Q4'25: -0.05× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
300.24M
est: 499.70M (-39.9%)
|
205.42M
est: 499.70M (-58.9%)
|
416.64M
est: 458.00M (-9.0%)
|
514.67M
est: 697.00M (-26.2%)
|
179.04M
est: 424.00M (-57.8%)
|
154.76M
est: 436.00M (-64.5%)
|
146.95M
est: 146.95M (+0.0%)
|
| EBITDA |
44.03M
est: 28.61M (+53.9%)
|
25.24M
est: 28.61M (-11.8%)
|
170.52M
est: 26.22M (+550.3%)
|
250.63M
est: 39.90M (+528.1%)
|
-48.12M
est: 24.27M (-298.2%)
|
-53.71M
est: 24.96M (-315.2%)
|
852.9K
est: 8.41M (-89.9%)
|
| EBIT |
23.63M
est: -8.47M (+378.9%)
|
13.28M
est: -8.47M (+256.8%)
|
161.73M
est: -7.77M (+2,182.2%)
|
236.89M
est: -11.82M (+2,104.1%)
|
-62.98M
est: -7.19M (-775.9%)
|
-73.14M
est: -7.39M (-889.2%)
|
-16.11M
est: -2.49M (-546.6%)
|
| Net Income |
14.90M
est: 25.77M (-42.2%)
|
-52.09M
est: 25.77M (-302.1%)
|
131.18M
est: 177.61M (-26.1%)
|
185.74M
est: 261.19M (-28.9%)
|
-55.69M
est: 41.79M (-233.3%)
|
-64.38M
est: 41.79M (-254.0%)
|
-13.92M
|
| SGA |
511.5K
est: 39.94M (-98.7%)
|
255.9K
est: 39.94M (-99.4%)
|
47.16M
est: 36.60M (+28.8%)
|
300.7K
est: 55.70M (-99.5%)
|
301.2K
est: 33.89M (-99.1%)
|
380.9K
est: 34.85M (-98.9%)
|
41.39M
est: 11.74M (+252.4%)
|
| EPS |
0.02
est: 0.02 (-11.6%)
|
-0.07
est: 0.02 (-378.9%)
|
0.16
est: 0.17 (-5.9%)
|
0.22
est: 0.25 (-12.0%)
|
-0.06
est: 0.04 (-255.5%)
|
-0.06
est: 0.04 (-260.8%)
|
-0.01
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chin Leng Khoo | Group MD & Director | 809.0K | male |
| Hsu-Ming Goh | Non-Independent Executive Director | 631.0K | male |
| Tong Lang Tan | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7803.KL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
